WASHINGTON, Sept. 24 -- The Senate Finance Committee issued the following news release:
Senate Finance Committee (Committee) Ranking Member Ron Wyden, D-Ore., today called on Donald Trump's nominee to be the second-in-command at the Department of Health and Human Services (HHS) to follow through on commitments to disclose agreements made between the federal government and pharmaceutical companies, before the Committee votes on his nomination.
"The Trump administration continues to use Oval Office fanfare to gaslight Congress and the American people, suggesting these agreements offer the United States the 'lowest prescription drug prices anywhere in the world,'" Wyden wrote. "There is absolutely no proof to back up this claim; in fact, all...